Eisai Co., Ltd. (4523.T)
| Previous Close | 6,753.00 |
| Open | 6,790.00 |
| Bid | 6,815.00 x 0 |
| Ask | 6,819.00 x 0 |
| Day's Range | 6,733.00 - 6,825.00 |
| 52 Week Range | 5,795.00 - 11,250.00 |
| Volume | |
| Avg. Volume | 1,323,009 |
| Market Cap | 1.957T |
| Beta (5Y Monthly) | -0.06 |
| PE Ratio (TTM) | 46.11 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 160.00 (2.37%) |
| Ex-Dividend Date | Sept 27, 2024 |
| 1y Target Est | N/A |
- Yahoo Finance
Alzheimer's drug Leqembi: The twice-monthly infusion could be available in injection form
An Alzheimer's drug in injectable form could be the key for Biogen, Eisai to ease pressures and concerns of a limited market and revenue.
- Yahoo Finance Video
Eisai reporting positive data on injectable Alzheimer’s drug
Japanese pharma company Eisai (ESAIY) reported positive results in clinical trials of its Alzheimer’s drug Leqembi. This could mean a revolution for administering the drug, which is currently only administered via IV. Yahoo Finance’s Anjalee Khemlani breaks down what this means in terms of access and costs as concerns about side effects and formularies are evident. Pfizer (PFE) and BioNTech (BNTX) are also working together to develop a combo COVID-flu vaccine, showing positive data in its trial. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
- Investing.com
Eisai's Alzheimer's drug Leqembi gets green light in Japan, shares surge
In a significant development for Eisai Co (OTC:ESAIY)., the Japanese health ministry has approved its innovative Alzheimer's disease medication, Leqembi. The decision, announced on Monday, follows a panel's recommendation in August and comes after the drug received full endorsement from the U.S. authorities in July.
